Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Greenwich LifeSciences Flamingo-01 Phase 3 Trial Which Is Evaluating GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences, Approved to Expand Into Five Largest European Countries

Author: Benzinga Newsdesk | February 27, 2024 07:09am

The Company's application to expand Flamingo-01 into Europe has been formally approved by Spain, France, Germany, Italy, and Poland.

Site initiation visits have been scheduled as early as the week of March 4, 2024.

Posted In: GLSI

07/01/2024 Equinix, Inc. (EQIX)

07/02/2024 Intel Corporation (INTC)

07/05/2024 AXT, Inc. (AXTI)

07/05/2024 Altimmune, Inc. (ALT)

07/09/2024 Li Auto Inc. (LI)

07/12/2024 Inari Medical, Inc. (NARI)

07/12/2024 Sprout Social, Inc. (SPT)